Dianthus Therapeutics, Inc. /DE/ Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount of $22.00 million as of 2020-06-30, per its 10-Q filed 2020-08-06.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions · last filed 2020-08-06
- 2020-06-30: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $22.00M.
- 2020-03-31: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $24.20M.
- 2019-12-31: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $15.70M.
- 2019-09-30: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $18.00M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount |
|---|---|
| 2020-06-30 | $22.00M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $24.20M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $15.70M 10-K · filed 2020-03-03 |
| 2019-09-30 | $18.00M 10-Q · filed 2019-11-13 |
| 2019-06-30 | $20.60M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $20.30M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $16.80M 10-K · filed 2019-03-19 |
| 2018-09-30 | $22.80M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $24.60M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |